Nothing
#' Bladder Cancer Recurrences.
#'
#' bladderCS is a data frame with 8 variables and 85 observations. Data on
#' recurrences of bladder cancer, used by many people to demonstrate
#' methodology for recurrent event modelling.
#'
#'
#' @name bladderCS
#' @docType data
#' @format A data frame with 85 observations on the following 8 variables.
#' Below a brief description is given for some of these variables.
#' \describe{
#' \item{t1}{Time to first recurrence/censoring, whichever occurs first.}
#' \item{e1}{Recurrence/censoring indicator (first recurrence=1) for the first
#' time (t1).} \item{t2}{Time to second recurrence/censoring, whichever occurs
#' first.} \item{e2}{Recurrence/censoring indicator (second recurrence=1) for
#' the second time (t2)} \item{t3}{Time to recurrence/censoring, whichever
#' occurs first.} \item{e3}{Recurrence/censoring indicator (third recurrence=1)
#' for the third time (t3)} \item{t4}{Time to fourth recurrence/censoring,
#' whichever occurs first.} \item{e4}{Recurrence/censoring indicator (fourth
#' recurrence=1) for the fourth time (t4)}
#' }
#' @references
#'
#' Byar, D. (1980) Veterans administration study of chemoprophylaxis for
#' recurrent stage i bladder tumors: Comparisons of placebo, pyridoxine and
#' topical thiotepa. Bladder Tumors and Other Topics in Urological Oncology,
#' 18:363--370.
#' @keywords datasets
#' @examples
#'
#' data(bladderCS)
#' head(bladderCS)
#'
NULL
#' Chemotherapy for Stage B/C colon cancer.
#'
#' These are data from one of the first successful trials of adjuvant
#' chemotherapy for colon cancer. Levamisole is a low-toxicity compound
#' previously used to treat worm infestations in animals; 5-FU is a moderately
#' toxic (as these things go) chemotherapy agent.
#'
#'
#' @name colonCS
#' @docType data
#' @format A data frame with 929 observations on the following 15 variables.
#' Below a brief description is given for some of these variables. \describe{
#' \item{time1}{Time to recurrence/censoring/death, whichever occurs first.}
#' \item{event1}{Recurrence/censoring indicator (recurrence=1, alive=0).}
#' \item{Stime}{Time to censoring/death, whichever occurs first.}
#' \item{event}{Death/censoring indicator (death=1, alive=0).}
#' \item{rx}{Treatment - Obs(ervation), Lev(amisole), Lev(amisole)+5-FU.}
#' \item{sex}{Sex indicator (male=1, female=0).} \item{age}{Age in years.}
#' \item{obstruct}{Obstruction of colon by tumour.} \item{perfor}{Perforation
#' of colon.} \item{adhere}{Adherence to nearby organs.} \item{nodes}{Number of
#' lymph nodes with detectable cancer.} \item{differ}{Differentiation of tumour
#' (1=well, 2=moderate, 3=poor).} \item{extent}{Extent of local spread
#' (1=submucosa, 2=muscle, 3=serosa, 4=contiguous structures).}
#' \item{surg}{Time from surgery to registration (0=short, 1=long).}
#' \item{node4}{More than 4 positive lymph nodes.} }
#' @references JA Laurie, CG Moertel, TR Fleming, HS Wieand, JE Leigh, J Rubin,
#' GW McCormack, JB Gerstner, JE Krook and J Malliard. Surgical adjuvant
#' therapy of large-bowel carcinoma: An evaluation of levamisole and the
#' combination of levamisole and fluorouracil: The North Central Cancer
#' Treatment Group and the Mayo Clinic. Journal of Clinical Oncology,
#' 7:1447-1456, 1989.
#'
#' DY Lin. Cox regression analysis of multivariate failure time data: the
#' marginal approach. Statistics in Medicine, 13:2233-2247, 1994.
#'
#' CG Moertel, TR Fleming, JS MacDonald, DG Haller, JA Laurie, PJ Goodman, JS
#' Ungerleider, WA Emerson, DC Tormey, JH Glick, MH Veeder and JA Maillard.
#' Levamisole and fluorouracil for adjuvant therapy of resected colon
#' carcinoma. New England Journal of Medicine, 332:352-358, 1990.
#'
#' CG Moertel, TR Fleming, JS MacDonald, DG Haller, JA Laurie, CM Tangen, JS
#' Ungerleider, WA Emerson, DC Tormey, JH Glick, MH Veeder and JA Maillard.
#' Fluorouracil plus Levamisole as and effective adjuvant therapy after
#' resection of stage II colon carcinoma: a final report. Annals of Internal
#' Medicine, 122:321-326, 1991.
#' @source The study is originally described in Laurie (1989).The main report
#' is found in Moertel (1990). This data set is closest to that of the final
#' report in Moertel (1991). A version of the data with less follow-up time was
#' used in the paper by Lin (1994).
#' @keywords datasets
#' @examples
#'
#' data(colonCS)
#' head(colonCS)
#'
NULL
#' condSURV:A package for
#' nonparametric estimation of the survival functions for ordered multivariate
#' failure time data.
#'
#' Newly developed methods for the estimation of the conditional survival
#' function are implemented in this package. The condSURV package implements
#' nonparametric and semiparametric estimators for these quantities. The
#' package also implements feasible estimation methods for these quantities
#' conditionally on current or past covariate measures. Other related
#' estimators are also implemented in the package. One of these estimators is
#' the Kaplan-Meier estimator typically assumed to estimate the survival
#' function. A modification of the Kaplan-Meier estimator, based on a
#' preliminary estimation (presmoothing) of the censoring probability for the
#' survival time, given the available information is also implemented.
#'
#'
#' @name condSURV-package
#' @aliases condSURV-package condSURV
#' @docType package
#' @author Luis Meira-Machado and Marta Sestelo.
#'
#' Maintainer: Marta Sestelo, sestelo@@uvigo.es
#' @references L. Meira-Machado, M. Sestelo, and A. Goncalves (2016).
#' Nonparametric estimation of the survival function for ordered multivariate
#' failure time data: a comparative study. Biometrical Journal, 58(3),
#' 623--634.
NULL
#' German Breast Cancer Study Data.
#'
#' gbcsCS is a data frame with 16 variables and 686 observations. Cancer
#' clinical trials are a rich source for examples of applications of methods
#' for the analysis of time to event. Willi Sauerbrei and Patrick Royston have
#' graciously provided us with data obtained from the German Breast Cancer
#' Study Group, which they used to illustrate methods for building prognostic
#' models (Sauerbrei and Royston, 1999). In the main study, a total of 720
#' patients with primary node positive breast cancer were recruited between
#' July 1984, and December 1989, (see Schmoor, Olschweski and Schumacher M.
#' 1996 and Schumacher et al. (1994)).
#'
#'
#' @name gbcsCS
#' @docType data
#' @format A data frame with 686 observations on the following 16 variables.
#' Below a brief description is given for some of these variables. \describe{
#' \item{rectime}{Time to recurrence/censoring, whichever occurs
#' first.}
#' \item{censrec}{Recurrence/censoring indicator (recurrence=1,
#' alive=0).}
#' \item{survtime}{Time to censoring/death, whichever occurs
#' first.}
#' \item{censdead}{Death/censoring indicator (death=1, alive=0).}
#' \item{age}{Age in years.}
#' \item{size}{Tumour size.}
#' #' \item{deathdate}{}
#' \item{diagdateb}{}
#' \item{estrg_recp}{}
#' \item{grade}{}
#' \item{hormone}{}
#' \item{id}{}
#' \item{nodes}{}
#' \item{prog_recp}{}
#' \item{recdate}{}
#' \item{menopause}{}
#' }
#' @references Schmoor, C., Sauerbrei, W. Bastert, G., Schumacher, M. (2000).
#' Role of Isolated Locoregional Recurrence of Breast Cancer: Results of Four
#' Prospective Studies. Journal of Clinical Oncology, 18(8), 1696-1708.
#'
#' Schumacher, M., Bastert, G., Bojar, H., Hiibner, K., Olschewski, M.,
#' Sauerbrei, W., Schmoor, C., Beyerle, C., Neumann, R.L.A. and Rauschecker,
#' H.F. for the German Breast Cancer Study Group (GBSG) (1994). A randomized 2
#' x 2 trial evaluating hormonal treatment and the duration of chemotherapy in
#' node-positive breast cancer patients. Journal of Clinical Oncology, 12,
#' 2086-2093.
#'
#' Hosmer, D.W. and Lemeshow, S. and May, S. (2008). Applied Survival Analysis:
#' Regression Modeling of Time to Event Data: Second Edition, John Wiley and
#' Sons Inc., New York, NY
#' @keywords datasets
#' @examples
#'
#' data(gbcsCS)
#' head(gbcsCS)
#'
NULL
Any scripts or data that you put into this service are public.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.